0.20
+0.0054(+2.77%)
Currency In USD
Address
4902 Eisenhower Boulevard
Tampa, FL 33634
United States of America
Phone
813 286 7900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
February 25, 2004
| Name | Title | Pay | Year Born |
| Ms. Janet Huffman | Chief Executive Officer, President, Chief Financial Officer, Secretary & Treasurer | 332,500 | 1972 |
| Mr. Charles L. Pope C.P.A. | Executive Chairman | 112,500 | 1952 |
| Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D. | Chief Clinical Officer | 0 | N/A |
| Dr. James P. Kelly M.A., M.D. | Chief Medical Officer | 0 | N/A |
| Mr. Greg Gironda | Head of Business Development | 0 | N/A |
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.